NCT05408663View on ClinicalTrials.gov

A Phase 1 Study of EXT608 in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

July 21, 2022

Primary Completion Date

June 13, 2023

Study Completion Date

June 13, 2023

Conditions
Safety Issues
Interventions
DRUG

EXT608

EXT608 is an investigational drug administered via subcutaneous injection

OTHER

Placebo

matching placebo administered via subcutaneous injection

Trial Locations (1)

66219

PRA, Lenexa

Sponsors
All Listed Sponsors
collaborator

Integrated Medical Development

INDUSTRY

collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

collaborator

Pharmaceutical Research Associates

OTHER

lead

Extend Biosciences Inc.

INDUSTRY